SVGI
MGX icon

Sozo Ventures GP II’s Metagenomi Therapeutics MGX Stock Holding History

Sozo Ventures GP II’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.33M Hold
581,577
– – 100% 1
2025
Q2 		$861K Hold
581,577
– – 100% 1
2025
Q1 		$1.01M Hold
581,577
– – 100% 1
2024
Q4 		$2.1M Hold
581,577
– – 100% 1
2024
Q3 		$1.26M Hold
581,577
– – 100% 1
2024
Q2 		$2.37M Hold
581,577
– – 100% 1
2024
Q1 		$6.14M Buy
+581,577
New +$6.69M 100% 1

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Sozo Ventures GP II's MGX Position: Q3 2025 in Review

Sozo Ventures GP II held its Metagenomi Therapeutics (MGX) position steady in Q3 2025 at 581,577 shares worth $1.33M. The position accounts for 100% of the portfolio, ranked #1.

Sozo Ventures GP II first reported a position in MGX in Q1 2024 and has held it in 7 quarters since. The position peaked at $6.14M in Q1 2024. 58 funds tracked by Wall St. Rank hold MGX as of Q3 2025.

  • Sozo Ventures GP II held 581,577 shares of Metagenomi Therapeutics worth $1.33M as of Q3 2025.
  • Sozo Ventures GP II left its Metagenomi Therapeutics share count unchanged in Q3 2025.
  • Metagenomi Therapeutics made up 100% of Sozo Ventures GP II's portfolio in Q3 2025, its #1 holding.
  • Sozo Ventures GP II first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Sozo Ventures GP II's Metagenomi Therapeutics position peaked at $6.14M in Q1 2024.
  • 58 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2025.

Based on Sozo Ventures GP II's 13F filing for Q3 2025, filed 6 Nov 2025.